Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Akcea Therapeutics, Inc., Alnylam Pharmaceuticals, and Pfizer, Inc.
Rare Disease Consultations™: Uncommon Presentations of hATTR Amyloidosis: Coordinating Care Between the Cardiologist and Neurologist
Release Date: September 10, 2020
Expiration Date: September 10, 2021
This Rare Disease ConsultationsTM activity is a video-based program in which two experts discuss the management of hereditary transthyretin-mediated (hATTR) amyloidosis. In this activity, the faculty will focus on current and emerging therapeutic strategies for managing hATTR amyloidosis and will discuss patient cases. This engaging format is designed to help clinicians identify best practices in the diagnosis and management of hATTR amyloidosis and to improve outcomes for patients with this disease.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Akcea Therapeutics, Inc,, Alnylam Pharmaceuticals, and Pfizer, Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate.
This online educational activity is primarily directed toward neurologists, cardiologists, and specialty NPs and PAs. Additional HCPs who have the opportunity to recognize red-flag symptoms of hATTR amyloidosis will be invited to participate such as critical care specialists, primary care physicians, ophthalmologists, nephrologists, pulmonologists, gastroenterologists, pathologists, NPs, PAs, and nurses.
Upon successful completion of this activity, you should be better prepared to:
• Identify red-flag symptoms and the role of genetic testing methods in accurately diagnosing hATTR amyloidosis
• Evaluate the efficacy and safety of current and emerging agents for the treatment of patients with hATTR amyloidosis
• Describe best practices for effective communication and coordination between cardiologists and neurologists to optimize patient outcomes
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Associate Professor, Harvard Medical School
Brigham and Women's Hospital,
Division of Cardiovascular Medicine
Disclosures: Grant Research Support: Pfizer, Akcea, Ion
Professor and Chief of Neurology
Penn Presbyterian Medical Center
University of Pennsylvania School of Medicine
Disclosures:Consultant: Alnylum, Akcea, Ionis, Eidos, Pfizer
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.